Skip to content
Open access

Strategies for Identifying Molecules of Interest in Large Chemical Spaces

Jul 2026 · Journal of Chemical Information and Modeling · Vol 66, pp. 8251 - 8268 · 2 citations · 40 references
Medicine Computer Science

Abstract

In recent years make-on-demand compound libraries (so-called Chemical Spaces) have gained more and more interest in pharmaceutical industry. Compound vendors promise cheap compounds, fast delivery, high synthetical accessibility and a large pool of novel chemical matter, fulfilling the requirements of fast Design-Make-Test cycles. Searching in ultralarge Chemical Spaces with known 2D similarity metrics, like fingerprint-based Tanimoto, substructure, or pharmacophore similarity searches, contains pitfalls due to the representation of molecules as synthons with connectivity rules. Applied to a set of almost 3000 drug-relevant queries we analyzed the ability of similarity search methods to retrieve analog compounds from Chemical Spaces, and how to best approach typical use cases in early phase drug discovery. Distinct characteristics of each similarity metric suggest orthogonal complementarity, enabling a versatile framework to diverse challenges present in hit discovery and lead expansion campaigns. Our investigations resulted in formulating practical considerations and guidelines for interpreting the scores including recommendations for thresholds for each similarity metric.

Read PDF

Similar papers

Open access Sep 2026

Pushing the boundaries of virtual screening scale of combinatorial spaces with the V-SYNTHES approach

The first application of the V-SYNTHES2 synthon-based screening approach to the 173-billion-compound Enamine xREAL Space is reported, demonstrating near-linear computational scaling with only a 10–15% increase in cost relative to the 11-billion-compound REAL Space.

Mykola V. Protopopov, Olha Semenenko, Maryna Vasylchuk et al. · 0 citations
Review Sep 2026

Exploring Optimal Parameters for Ligand-Based Virtual Screening in Early Drug Discovery

The results support a staged screening design in which a pooled default is followed by ligand-specific calibration and expert review, and SCScore showed the highest association with the blinded consensus, but performance varied by ligand.

T. Sobodu, Victor Chibuzor Johnson, Ryan Kern et al. · 0 citations
Open access Sep 2026

The Scope Concept: Defined Chemical Space for Identifying Ligand-Efficient, Tractable Hits Applied to Drug Discovery Targets Trypanosomal CLK1, 14–3–3/Estrogen Receptor-α, and SARS-CoV-2 Mpro

Scope is a hit-finding concept that explores a chemical space in between fragments and fully elaborated molecules from traditional low molecular weight (LMW) libraries. It emphasizes high medicinal chemistry tractability through a focus on compound quality, ligand efficiency, and selected physical-chemical property r...

J. Jansen, Wilian A. Cortopassi, Daniel Fuller et al. · 1 citation
Open access Aug 2026

Expanding accessible chemical space for fragment-based enumeration by orders of magnitude through optimization of the Chemically Reasonable Mutations (CReM) framework

The size of synthetically accessible small molecule chemical space has rapidly grown to billions, and even trillions, of molecules, unlocking tremendous new opportunities for drug discovery. Fully leveraging these ultralarge chemical libraries, however, will strain existing computational tools, requiring novel appr...

Shaojin Hu, Qin-Yu Chen, Yinhui Yi et al. · 0 citations
Aug 2026

Systematic Benchmarking of AI-Based Molecular Generation Models for Structure-Based Drug Design

A state-aware functional classifier (SAFC) is developed that integrates molecular dynamics derived receptor ensembles, ensemble docking and protein ligand interaction graphs that provides dynamics-aware functional activity rankings for generated molecules that were partly complementary to docking, drug-likeness and syn...

H. Kumar, Zheng-Xiao Yang, Yankai Yu et al. · 0 citations
Open access Sep 2026

AI-enhanced adaptive virtual screening of large libraries for ligand discovery.

Ultralarge virtual screenings (ULVSs) evaluate billions of molecules for drug discovery but face cost, flexibility and scalability limits. We introduce AdaptiveFlow, an open-source platform that makes ULVSs more accessible, scalable and efficient and supports artificial intelligence (AI) and machine learning (ML) metho...

Domiziana Cecchini, AkshatKumar Nigam, Ming Tang et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.